Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases

Yash Gupta; Riya Shikha; Vishal Rai; Nisha Bano; Soban Khan; Reena Yadav

doi:10.55544/jrasb.3.1.25

Authors

Yash Gupta Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Riya Shikha Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Vishal Rai Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Nisha Bano Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Soban Khan Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.
Reena Yadav Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.1.25

Keywords:

Bilirubin, Heme catabolism, Reactive Oxygen Species (ROS)

Abstract

Bilirubin, a natural product of heme catabolism, has recently emerged as a promising candidate in nanomedicine for the treatment of Reactive Oxygen Species (ROS)-mediated diseases. ROS, including free radicals and other oxygen-derived molecules, play a pivotal role in various pathological conditions such as inflammation, neurodegenerative disorders, and cardiovascular diseases. Bilirubin's potent antioxidant properties make it an attractive therapeutic agent, and recent advancements in nanotechnology have paved the way for its effective delivery and application in treating ROS-related ailments.This abstract delves into the potential of bilirubin-based nanomedicines in combating ROS-induced damage. The encapsulation of bilirubin within nanocarriers enhances its stability, bioavailability, and targeted delivery to affected tissues. The utilization of nanoscale systems not only safeguards bilirubin from degradation but also allows for controlled release, ensuring sustained therapeutic effects.The multifaceted mechanisms of bilirubin action include its ability to scavenge free radicals, modulate inflammatory responses, and protect cellular components from oxidative stress. The encapsulation of bilirubin in nanoparticles further improves its pharmacokinetics, enabling efficient distribution and accumulation at disease sites. Moreover, the nanocarrier systems can be engineered to respond to specific stimuli, facilitating site-specific release of bilirubin in response to the elevated ROS levels characteristic of pathological conditions.This abstract also highlights the versatility of bilirubin nanomedicines in addressing diverse ROS-mediated diseases. From neuroprotection in conditions like Alzheimer's and Parkinson's diseases to alleviating oxidative stress in cardiovascular disorders, bilirubin-based nanotherapeutics exhibit a broad spectrum of applications. The tailored design of nanocarriers allows for personalized treatment approaches, catering to the unique characteristics of each disease state.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Vaz AR, Silva SL, Barateiro A, et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev. 2015 Dec;28(2): 109-25.

Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.

Mancuso C, Santangelo R. Alzheimer's disease and gut microbiota modifications: the long way between preclinical studies and clinical evidence. Pharmacol Res. 2018;129:329-36.

Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016;167(6):1469-80.e12.

Cenit MC, Sanz Y, Codoner-Franch P. Influence of gut microbiota on neuropsychiatric disorders. World J Gastroenterol. 2017;23(30):5486-98.

Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016;167(4):915-32.

Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am. 2017;46(1):77-89.

Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34(46):15490-6.

Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-9.

Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305-12.

Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735-42.

Cryan JF, O'Riordan KJ, Cowan CSM, et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877-2013.

Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe. 2015;17(5):565-76.

Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-63.

Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014;20(9):509-18.

Erny D, Hrabe de Angelis AL, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965-77.

Braniste V, Al-Asmakh M, Kowal C, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158.

Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2015;9:392.

Bruce-Keller AJ, Salbaum JM, Berthoud HR. Harnessing Gut Microbes for Mental Health: Getting From Here to There. Biol Psychiatry. 2018;83(3):214-23.

Sylvia KE, Jewell CP, Rendon NM, St John EA, Demas GE. Sex-specific modulation of the gut microbiome and behavior in Siberian hamsters. Brain Behav Immun. 2017;60:51-62.

Zheng P, Zeng B, Liu M, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv. 2019;5(2):eaau8317.

Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-32.

Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-94.

Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, et al. Bifidobacterium and Lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls. Front Psychiatry. 2018;9:730.

Dickerson F, Adamos M, Katsafanas E, et al. The association between the gut microbiome and schizophrenia: the role of tryptophan metabolism. Schizophr Res. 2018;202:483-9.

Jiang HY, Zhang X, Yu ZH, et al. Altered gut microbiota profile in patients with generalized anxiety disorder. J Psychiatr Res. 2018;104:130-6.

Zheng P, Yang J, Li Y, et al. Gut microbial signatures can discriminate unipolar from bipolar depression. Adv Sci (Weinh). 2020;7(17):1902862.

Chen Z, Li J, Gui S, et al. Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder. Neuroreport. 2018;29(5):417-25.

Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565-9.

Liu S, Li E, Sun Z, et al. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci Rep. 2019;9(1):287.

Shirzadfar, M., et al. (2019). A comprehensive study over the jaundice causes and effects on newborns and reviewing the treatment effects. International Journal of Biosensors & Bioelectronics, 5(3), 68-72.

Zhang, Y., et al. (2020). Bilirubin nanomedicines for the treatment of reactive oxygen species (ROS)-mediated diseases. Journal of Controlled Release, 326, 583-598.